HALIFAX, NOVA SCOTIA – March 10, 2017 – NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or the “Company”) has closed its previously announced non-brokered private placement by raising $700,000 through the issuance of 3,500,000 Units at a price of $0.20 per unit. Each unit is comprised of one common share of the Company and a one-half common share purchase warrant. Two half warrants entitle the holder to acquire one common share of the Company for $0.35 for a period of 24 months from the closing date. All securities issued pursuant to this private placement are subject to a 4 month hold period that expires on July 11, 2017.

Certain officers, directors and insiders of the Company subscribed for an aggregate of 1,384,000 units.

The proceeds from the private placement will be used for general working capital purposes. The private placement remains subject to final acceptance by the TSX Venture Exchange.

Nova Leap is also pleased to announce an agreement (the “Agreement”) with Renmark Financial Communications Inc. (“Renmark”) to handle its investor relations activities in compliance with regulatory guidelines.

Renmark serves as the information conduit between C-suite management of publicly traded companies and registered financial advisors. Founded in 1999, Renmark has operations in Toronto and Montreal. Representing Nova Leap is John Boidman, Vice president of Renmark. John holds the CPIR designation and has been with Renmark since January 2000.

“We are pleased to announce that we have selected Renmark to reinforce Nova Leap’s profile in the financial community and enhance the visibility of our company. We choose Renmark because its standards and methodologies fit best with the message we wish to communicate to the investing public,” noted Chris Dobbin President and CEO.

In consideration of the services to be provided, the monthly fees incurred by Nova Leap will be a cash consideration of up to $8,000 CDN, starting March 1, 2017 for a period of six months ending on August 31, 2017 and monthly thereafter. Nova Leap and Renmark are unrelated and unaffiliated entities. Renmark does not have any interest, directly or indirectly, in Nova Leap or its securities, or any right or intent to acquire such an interest. The Agreement is subject to regulatory approval.

For further information:

Christopher Dobbin, Director, President and CEO
Nova Leap Health Corp.,
T: 902 401 9480
F: 902 482 5177
cdobbin@novaleaphealth.com

John Boidman, Vice President
Renmark Financial Communications Inc.
T: 416 644-2020 or 514 939-3989
jboidman@renmarkfinancial.com

CAUTIONARY STATEMENT:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

(Not for distribution to US wire services or for dissemination in the United States of America)